ES2556639T3 - Método para usar células no raras para detectar células raras - Google Patents
Método para usar células no raras para detectar células raras Download PDFInfo
- Publication number
- ES2556639T3 ES2556639T3 ES10825626.4T ES10825626T ES2556639T3 ES 2556639 T3 ES2556639 T3 ES 2556639T3 ES 10825626 T ES10825626 T ES 10825626T ES 2556639 T3 ES2556639 T3 ES 2556639T3
- Authority
- ES
- Spain
- Prior art keywords
- ctc
- marker
- cells
- cell
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title abstract description 27
- 239000003550 marker Substances 0.000 abstract description 50
- 210000000265 leukocyte Anatomy 0.000 abstract description 22
- 102000011782 Keratins Human genes 0.000 abstract description 7
- 108010076876 Keratins Proteins 0.000 abstract description 7
- 230000001413 cellular effect Effects 0.000 abstract description 6
- 238000003384 imaging method Methods 0.000 abstract description 6
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 abstract description 4
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 abstract description 4
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 abstract description 3
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 abstract description 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 abstract 1
- 239000002771 cell marker Substances 0.000 abstract 1
- 210000005266 circulating tumour cell Anatomy 0.000 description 88
- 210000004027 cell Anatomy 0.000 description 65
- 239000000523 sample Substances 0.000 description 20
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 238000009826 distribution Methods 0.000 description 13
- 210000003743 erythrocyte Anatomy 0.000 description 13
- 206010028980 Neoplasm Diseases 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 238000012512 characterization method Methods 0.000 description 8
- 238000001514 detection method Methods 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 6
- 210000004940 nucleus Anatomy 0.000 description 6
- 239000000306 component Substances 0.000 description 5
- 238000003908 quality control method Methods 0.000 description 5
- 238000013459 approach Methods 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000012503 blood component Substances 0.000 description 3
- 210000001772 blood platelet Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 230000002028 premature Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 206010061819 Disease recurrence Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 210000003651 basophil Anatomy 0.000 description 2
- 230000009141 biological interaction Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000003312 immunocapture Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 238000000399 optical microscopy Methods 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 210000004910 pleural fluid Anatomy 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 102100032187 Androgen receptor Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102100035186 DNA excision repair protein ERCC-1 Human genes 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102100027100 Echinoderm microtubule-associated protein-like 4 Human genes 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 101000876529 Homo sapiens DNA excision repair protein ERCC-1 Proteins 0.000 description 1
- 101001057929 Homo sapiens Echinoderm microtubule-associated protein-like 4 Proteins 0.000 description 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101001074727 Homo sapiens Ribonucleoside-diphosphate reductase large subunit Proteins 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010008707 Mucin-1 Proteins 0.000 description 1
- 102100034256 Mucin-1 Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102100021768 Phosphoserine aminotransferase Human genes 0.000 description 1
- 239000004696 Poly ether ether ketone Substances 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 102100036320 Ribonucleoside-diphosphate reductase large subunit Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 229920006397 acrylic thermoplastic Polymers 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- JUPQTSLXMOCDHR-UHFFFAOYSA-N benzene-1,4-diol;bis(4-fluorophenyl)methanone Chemical compound OC1=CC=C(O)C=C1.C1=CC(F)=CC=C1C(=O)C1=CC=C(F)C=C1 JUPQTSLXMOCDHR-UHFFFAOYSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- -1 cMET Proteins 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000000205 computational method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000003583 cytomorphological effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 229920002313 fluoropolymer Polymers 0.000 description 1
- 239000004811 fluoropolymer Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000005033 mesothelial cell Anatomy 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 230000004987 nonapoptotic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920002530 polyetherether ketone Polymers 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 102000003998 progesterone receptors Human genes 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6875—Nucleoproteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Physiology (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Image Processing (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25378709P | 2009-10-21 | 2009-10-21 | |
| US253787P | 2009-10-21 | ||
| PCT/US2010/053431 WO2011050103A1 (en) | 2009-10-21 | 2010-10-20 | Method of using non-rare cells to detect rare cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2556639T3 true ES2556639T3 (es) | 2016-01-19 |
Family
ID=43900673
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10825626.4T Active ES2556639T3 (es) | 2009-10-21 | 2010-10-20 | Método para usar células no raras para detectar células raras |
| ES15185229.0T Active ES2661735T3 (es) | 2009-10-21 | 2010-10-20 | Método para usar células no raras para detectar células raras |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15185229.0T Active ES2661735T3 (es) | 2009-10-21 | 2010-10-20 | Método para usar células no raras para detectar células raras |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US20120276555A1 (enExample) |
| EP (3) | EP2491395B1 (enExample) |
| JP (3) | JP6352588B2 (enExample) |
| CN (3) | CN107422127A (enExample) |
| AU (4) | AU2010310688A1 (enExample) |
| CA (1) | CA2778328C (enExample) |
| ES (2) | ES2556639T3 (enExample) |
| WO (1) | WO2011050103A1 (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2556639T3 (es) | 2009-10-21 | 2016-01-19 | The Scripps Research Institute | Método para usar células no raras para detectar células raras |
| JP5716738B2 (ja) * | 2010-03-05 | 2015-05-13 | コニカミノルタ株式会社 | 細胞の検出方法及び細胞検出システム |
| JP5916991B2 (ja) * | 2010-11-09 | 2016-05-11 | オリンパス株式会社 | 遺伝子異常細胞の解析方法 |
| BR112014000329A2 (pt) * | 2011-07-07 | 2017-02-07 | Scripps Health | método de análise de distúrbios cardiovasculares e uso do mesmo |
| US10813630B2 (en) | 2011-08-09 | 2020-10-27 | Corquest Medical, Inc. | Closure system for atrial wall |
| US10307167B2 (en) | 2012-12-14 | 2019-06-04 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
| US10314594B2 (en) | 2012-12-14 | 2019-06-11 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
| WO2013109944A1 (en) * | 2012-01-18 | 2013-07-25 | The Trustees Of The University Of Pennsylvania | Methods for assessing risk for cancer using biomarkers |
| JP6254951B2 (ja) | 2012-01-24 | 2017-12-27 | ファイザー・インク | 哺乳類の対象における５ｔ４陽性循環腫瘍細胞を検出するための方法および５ｔ４陽性がんの診断の方法 |
| US20140142689A1 (en) | 2012-11-21 | 2014-05-22 | Didier De Canniere | Device and method of treating heart valve malfunction |
| US9690976B2 (en) * | 2013-03-11 | 2017-06-27 | Roche Diagnostics Hematology, Inc. | Imaging blood cells |
| US10222304B2 (en) | 2013-03-15 | 2019-03-05 | Massachusetts Institute Of Technology | Deposition and imaging of particles on planar substrates |
| US10225483B1 (en) * | 2013-05-01 | 2019-03-05 | Pierce Biotechnology, Inc. | Method and system for projecting image with differing exposure times |
| US10115034B2 (en) * | 2013-05-01 | 2018-10-30 | Life Technologies Holdings Pte Limited | Method and system for projecting image with differing exposure times |
| JP6453592B2 (ja) | 2013-09-25 | 2019-01-16 | アークレイ株式会社 | 血液検体の処理方法 |
| WO2015048740A1 (en) | 2013-09-30 | 2015-04-02 | The Scripps Research Institute | Genotypic and phenotypic analysis of circulating tumor cells to monitor tumor evolution in prostate cancer patients |
| US10053692B2 (en) | 2013-10-21 | 2018-08-21 | The General Hospital Corporation | Methods relating to circulating tumor cell clusters and the treatment of cancer |
| US9566443B2 (en) | 2013-11-26 | 2017-02-14 | Corquest Medical, Inc. | System for treating heart valve malfunction including mitral regurgitation |
| EP3080245B1 (en) * | 2013-12-09 | 2021-05-26 | The Scripps Research Institute | Methods for the detection and quantification of circulating endothelial cells |
| US10147180B2 (en) | 2013-12-19 | 2018-12-04 | Axon Dx, Llc | Cell detection, capture and isolation methods and apparatus |
| US20160011198A1 (en) * | 2014-01-27 | 2016-01-14 | Epic Sciences, Inc. | Detection of prostate specific membrane antigen (psma) expression on circulating tumor cells (ctc) |
| EP3100047B1 (en) * | 2014-01-27 | 2021-08-11 | Epic Sciences, Inc. | Circulating tumor cell diagnostics for prostate cancer biomarkers |
| EP3099821B1 (en) * | 2014-01-27 | 2021-08-11 | Epic Sciences, Inc. | Circulating tumor cell diagnostics for detection of neuroendocrine prostate cancer (nepc) |
| WO2015116828A1 (en) * | 2014-01-30 | 2015-08-06 | Epic Sciences, Inc. | Circulating tumor cell diagnostics for biomarkers predictive of resistance to androgen receptor (ar) targeted therapies |
| EA201691497A1 (ru) * | 2014-01-31 | 2017-01-30 | Эпик Сайенсиз, Инк. | Способы детектирования и количественного определения имитаторов циркулирующих опухолевых клеток |
| EP3108246B1 (en) | 2014-02-21 | 2019-10-09 | Epic Sciences, Inc. | Methods for analyzing rare circulating cells |
| EA201692223A1 (ru) * | 2014-05-09 | 2017-04-28 | Дзе Скриппс Рисерч Инститьют | Композиции и способы жидкостной биопсии меланомы |
| US20170285035A1 (en) * | 2014-09-25 | 2017-10-05 | Epic Sciences, Inc. | Circulating tumor cell diagnostics for identification of resistance to androgen receptor targeted therapies |
| US10823736B2 (en) * | 2014-09-26 | 2020-11-03 | The Regents Of The University Of California | Method of assessing disease condition of cancer |
| US10842626B2 (en) | 2014-12-09 | 2020-11-24 | Didier De Canniere | Intracardiac device to correct mitral regurgitation |
| JP6737185B2 (ja) * | 2015-01-29 | 2020-08-05 | コニカミノルタ株式会社 | 相互作用する分子を有する血中細胞の同時検出方法 |
| CN108064343B (zh) * | 2015-04-21 | 2021-07-09 | 基因泰克公司 | 用于前列腺癌分析的组合物和方法 |
| EP3303363A4 (en) * | 2015-05-29 | 2019-01-23 | Epic Sciences, Inc. | INTRAPATIENT GENOMHETEROGENICITY OF INDIVIDUAL CIRCULATIVE TUMOR CELLS (CTCS) RELATED TO PHENOTYPIC CTC HETEROGENICITY IN METASTASED, CASTING RESISTANT PROSTATE CANCER (MCRPC) |
| US20180328848A1 (en) * | 2015-11-04 | 2018-11-15 | Axon Dx, Llc | Cell detection, capture, analysis, aggregation, and output methods and apparatus |
| WO2017126634A1 (ja) * | 2016-01-19 | 2017-07-27 | 東ソー株式会社 | 希少細胞を用いて癌患者の予後を予測する方法 |
| US9739783B1 (en) * | 2016-03-15 | 2017-08-22 | Anixa Diagnostics Corporation | Convolutional neural networks for cancer diagnosis |
| US10360499B2 (en) | 2017-02-28 | 2019-07-23 | Anixa Diagnostics Corporation | Methods for using artificial neural network analysis on flow cytometry data for cancer diagnosis |
| US11164082B2 (en) | 2017-02-28 | 2021-11-02 | Anixa Diagnostics Corporation | Methods for using artificial neural network analysis on flow cytometry data for cancer diagnosis |
| US9934364B1 (en) | 2017-02-28 | 2018-04-03 | Anixa Diagnostics Corporation | Methods for using artificial neural network analysis on flow cytometry data for cancer diagnosis |
| CN108646034B (zh) * | 2018-07-03 | 2020-10-23 | 珠海圣美生物诊断技术有限公司 | 细胞群中的稀有细胞判读方法 |
| CN111079579B (zh) * | 2019-12-02 | 2023-07-25 | 英华达（上海）科技有限公司 | 细胞图像的识别方法、装置以及系统 |
| KR20220010132A (ko) | 2020-07-17 | 2022-01-25 | 주식회사 엘지에너지솔루션 | 고로딩 전극을 위한 집전체용 시트의 압연 방법 및 고로딩 전극 |
| WO2022024564A1 (ja) * | 2020-07-30 | 2022-02-03 | 浜松ホトニクス株式会社 | 判別装置、判別方法、判別プログラム及び記録媒体 |
| CN113567672A (zh) * | 2021-07-26 | 2021-10-29 | 江南大学附属医院 | 一种检测腹水或腹腔灌洗液中癌细胞的试剂盒 |
| WO2023107566A1 (en) * | 2021-12-07 | 2023-06-15 | Epic Sciences, Inc. | Enhanced characterization of breast cancer |
| CN114910455B (zh) * | 2022-05-06 | 2025-06-20 | 马海燕 | 一种稀有单细胞识别轮廓的可视化的方法 |
Family Cites Families (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6197523B1 (en) | 1997-11-24 | 2001-03-06 | Robert A. Levine | Method for the detection, identification, enumeration and confirmation of circulating cancer and/or hematologic progenitor cells in whole blood |
| CA2253965C (en) | 1997-11-22 | 2003-01-21 | Robert A. Levine | Method for the detection, identification, enumeration and confirmation of circulating cancer cells and/or hematologic progenitor cells in whole blood |
| US20010018058A1 (en) | 1997-12-24 | 2001-08-30 | Reed Steven G. | Compounds for immunotherapy and diagnosis of breast cancer and methods for their use |
| US8192994B2 (en) | 1998-02-10 | 2012-06-05 | Angros Lee H | Method of applying a biological specimen to an analytic plate |
| EP1062515B1 (en) | 1998-02-12 | 2009-11-25 | Immunivest Corporation | Methods and reagents for the rapid and efficient isolation of circulating cancer cells |
| EP1078257A4 (en) | 1998-05-09 | 2007-07-18 | Iconisys Inc | METHOD AND APPARATUS FOR COMPUTER-ASSISTED DIAGNOSIS OF RARE CELLS, INCLUDING FETAL CELLS |
| WO2000047998A1 (en) | 1999-02-10 | 2000-08-17 | Cell Works Inc. | Class characterization of circulating cancer cells isolated from body fluids and methods of use |
| WO2001094528A2 (en) * | 2000-06-08 | 2001-12-13 | The Regents Of The University Of California | Visual-servoing optical microscopy |
| US7546210B2 (en) * | 2000-06-08 | 2009-06-09 | The Regents Of The University Of California | Visual-servoing optical microscopy |
| US7033832B2 (en) | 2000-10-13 | 2006-04-25 | University Of Medicine And Dentistry Of New Jersey | Endothelial cell—cell cohesion |
| AU2002249481A1 (en) | 2000-10-25 | 2002-08-12 | Exiqon A/S | Open substrate platforms suitable for analysis of biomolecules |
| US6701197B2 (en) | 2000-11-08 | 2004-03-02 | Orbotech Ltd. | System and method for side to side registration in a printed circuit imager |
| DE60233301D1 (de) | 2001-05-04 | 2009-09-24 | Biosite Inc | Diagnostische marker für akute herzerkrankungen und verfahren des gebrauchs |
| US20080009019A1 (en) * | 2001-06-13 | 2008-01-10 | Smithkline Beecham Corporation | High throughput method for screening candidate compounds for biological activity |
| US7863012B2 (en) | 2004-02-17 | 2011-01-04 | Veridex, Llc | Analysis of circulating tumor cells, fragments, and debris |
| JP2005501236A (ja) * | 2001-08-23 | 2005-01-13 | イムニベスト・コーポレイション | 分析用の細胞および生物学的検体の安定化 |
| US7943093B2 (en) | 2001-12-12 | 2011-05-17 | Erie Scientific Company | Cover slip |
| AU2003219759B2 (en) * | 2002-02-14 | 2011-01-20 | Veridex, Llc | Methods and algorithms for cell enumeration in a low-cost cytometer |
| US7113624B2 (en) | 2002-10-15 | 2006-09-26 | Palo Alto Research Center Incorporated | Imaging apparatus and method employing a large linear aperture |
| US7305112B2 (en) | 2002-10-15 | 2007-12-04 | The Scripps Research Institute | Method of converting rare cell scanner image coordinates to microscope coordinates using reticle marks on a sample media |
| US7282180B2 (en) * | 2003-07-02 | 2007-10-16 | Immunivest Corporation | Devices and methods to image objects |
| US7372985B2 (en) * | 2003-08-15 | 2008-05-13 | Massachusetts Institute Of Technology | Systems and methods for volumetric tissue scanning microscopy |
| USRE46379E1 (en) * | 2004-04-08 | 2017-04-25 | Cornell Research Foundation, Inc. | Functional immunohistochemical cell cycle analysis as a prognostic indicator for cancer |
| WO2006041453A1 (en) | 2004-09-30 | 2006-04-20 | Immunivest Corporation | Circulating tumor cells (ctc’s): apoptotic assessment in prostate cancer patients |
| EP1825317B1 (en) * | 2004-11-24 | 2013-04-17 | Battelle Memorial Institute | Optical system for cell imaging |
| US7280261B2 (en) | 2004-12-20 | 2007-10-09 | Palo Alto Research Center Incorporated | Method of scanning and light collection for a rare cell detector |
| US20090081688A1 (en) * | 2005-06-20 | 2009-03-26 | Advanced Cell Diagnostics | Methods of detecting nucleic acids in individual cells and of identifying rare cells from large heterogeneous cell populations |
| US20070009389A1 (en) | 2005-07-08 | 2007-01-11 | Antti Seppo | Slide deposition chamber |
| US9134237B2 (en) | 2005-09-20 | 2015-09-15 | Janssen Diagnotics, LLC | High sensitivity multiparameter method for rare event analysis in a biological sample |
| ES2420834T3 (es) * | 2006-01-30 | 2013-08-27 | The Scripps Research Institute | Métodos de detección de células tumorales circulantes y métodos de diagnóstico del cáncer en un sujeto mamífero |
| US8337755B2 (en) * | 2006-03-13 | 2012-12-25 | Veridex, Llc | Operator independent programmable sample preparation and analysis system |
| US20080076727A1 (en) | 2006-03-29 | 2008-03-27 | John Wayne Cancer Institute | Utility of high molecular weight melanoma associated antigen in diagnosis and treatment of cancer |
| WO2007131507A2 (en) * | 2006-05-13 | 2007-11-22 | Dako Denmark A/S | Methods for flow cytometry analyses of cells without lysing subpopulations |
| EP2027470B1 (en) * | 2006-06-02 | 2012-11-21 | Pfizer Products Inc. | Circulating tumor cell assay |
| WO2008111990A1 (en) * | 2006-06-14 | 2008-09-18 | Cellpoint Diagnostics, Inc. | Rare cell analysis using sample splitting and dna tags |
| EP2041299A4 (en) * | 2006-07-14 | 2010-01-13 | Aviva Biosciences Corp | METHOD AND COMPOSITIONS FOR DETECTION OF RARE CELLS FROM A BIOLOGICAL SAMPLE |
| US20080113358A1 (en) * | 2006-07-28 | 2008-05-15 | Ravi Kapur | Selection of cells using biomarkers |
| JP5548890B2 (ja) * | 2006-09-05 | 2014-07-16 | ジャンセン ダイアグノスティックス，エルエルシー | 細胞の画像を格付けするための方法 |
| US8244021B2 (en) | 2006-12-20 | 2012-08-14 | Ventana Medical Systems, Inc. | Quantitative, multispectral image analysis of tissue specimens stained with quantum dots |
| CN101226118B (zh) | 2007-01-19 | 2010-06-16 | 中国医学科学院肿瘤研究所 | 一种兼容免疫荧光分析的细胞化学染色方法及其用途 |
| EP2155856A4 (en) | 2007-06-05 | 2013-06-26 | Nanopoint Inc | SYSTEMS AND METHODS OF CELL TRAY |
| WO2009038754A2 (en) | 2007-09-19 | 2009-03-26 | The Research Foundation Of State University Of New York | Gene expression signatures in enriched tumor cell samples |
| WO2009051734A1 (en) * | 2007-10-17 | 2009-04-23 | The General Hospital Corporation | Microchip-based devices for capturing circulating tumor cells and methods of their use |
| WO2009064933A2 (en) | 2007-11-13 | 2009-05-22 | Ikonisys, Inc. | Detection of circulating tumor cells in peripheral blood with an automated scanning fluorescence microscope |
| US20090258365A1 (en) | 2008-03-25 | 2009-10-15 | Terstappen Leon W M M | METHOD FOR DETECTING IGF1R/Chr 15 in CIRCULATING TUMOR CELLS USING FISH |
| US20110189670A1 (en) | 2008-07-07 | 2011-08-04 | Ruth L Katz | Circulating Tumor and Tumor Stem Cell Detection Using Genomic Specific Probes |
| US9779213B2 (en) | 2008-07-25 | 2017-10-03 | Fundacao D. Anna Sommer Champalimaud E Dr. Carlos Montez Champalimaud | System for evaluating a pathological stage of prostate cancer |
| US8324280B2 (en) | 2008-08-07 | 2012-12-04 | The University Of British Columbia | Treatment of prostate cancer with DDC inhibitor |
| WO2010028160A1 (en) | 2008-09-05 | 2010-03-11 | The Scripps Research Institute | Methods for the detection of circulating tumor cells |
| ES2556639T3 (es) | 2009-10-21 | 2016-01-19 | The Scripps Research Institute | Método para usar células no raras para detectar células raras |
| EP3029460A1 (en) | 2010-01-27 | 2016-06-08 | Duke University | O-cadherin as a biomarker for circulating tumor cells |
| CA2791244A1 (en) | 2010-03-08 | 2011-09-15 | Regents Of The University Of Minnesota | Androgen receptor isoforms and methods |
| TWI539158B (zh) | 2010-06-08 | 2016-06-21 | 維里德克斯有限責任公司 | 使用血液中之循環黑色素瘤細胞預測黑色素瘤病患之臨床結果的方法。 |
| US20140031250A1 (en) | 2010-10-07 | 2014-01-30 | David Tsai Ting | Biomarkers of Cancer |
| KR20190002733A (ko) | 2010-12-30 | 2019-01-08 | 파운데이션 메디신 인코포레이티드 | 종양 샘플의 다유전자 분석의 최적화 |
| AU2012209329A1 (en) | 2011-01-24 | 2013-09-12 | Epic Sciences, Inc. | Methods for obtaining single cells and applications of single cell omics |
| BR112014000329A2 (pt) | 2011-07-07 | 2017-02-07 | Scripps Health | método de análise de distúrbios cardiovasculares e uso do mesmo |
| US20130078667A1 (en) | 2011-09-22 | 2013-03-28 | Oscar B. Goodman | Methods for detecting and collecting circulating tumor cells |
| WO2013049926A1 (en) | 2011-10-06 | 2013-04-11 | UNIVERSITé LAVAL | PROGNOSTIC MARKERS OF INHERITED VARIATIONS IN THE 17β-HYDROXYSTEROID DEHYDROGENASE (HSD17B) GENES FOR PROSTATE CANCER |
| EP2788773A4 (en) | 2011-12-09 | 2015-09-09 | Scripps Research Inst | DEVICE, SYSTEM AND METHOD FOR IDENTIFYING CIRCULATING TUMOR CELLS |
| US20130171642A1 (en) | 2011-12-30 | 2013-07-04 | Ventana Medical Systems, Inc. | Automated analysis of circulating tumor cells |
| JP6254951B2 (ja) | 2012-01-24 | 2017-12-27 | ファイザー・インク | 哺乳類の対象における５ｔ４陽性循環腫瘍細胞を検出するための方法および５ｔ４陽性がんの診断の方法 |
| ES2917399T3 (es) | 2012-06-01 | 2022-07-08 | Creatv Microtech Inc | Captura, identificación y uso de un nuevo marcador de tumores sólidos en fluidos corporales |
| US9766244B2 (en) | 2012-07-02 | 2017-09-19 | The General Hospital Corporation | Diagnosis and monitoring treatment of prostate cancer |
| US20140024024A1 (en) | 2012-07-17 | 2014-01-23 | General Electric Company | Methods of detecting dna, rna and protein in biological samples |
| US9671405B2 (en) | 2012-09-19 | 2017-06-06 | Cornell University | Identifying taxane sensitivity in prostate cancer patients |
| EP2912194B1 (en) | 2012-10-26 | 2019-05-08 | Memorial Sloan-Kettering Cancer Center | Androgen receptor variants and methods for making and using |
| DE112013006579B4 (de) | 2013-02-02 | 2024-09-05 | Duke University | Verfahren zum Isolieren zirkulierender Tumorzellen |
| JP6483082B2 (ja) | 2013-03-15 | 2019-03-13 | ジェネンテック， インコーポレイテッド | Ｐｄ−１及びｐｄ−ｌ１に関連する状態を治療するためのバイオマーカー及び方法 |
| WO2015048740A1 (en) | 2013-09-30 | 2015-04-02 | The Scripps Research Institute | Genotypic and phenotypic analysis of circulating tumor cells to monitor tumor evolution in prostate cancer patients |
| WO2015073896A2 (en) | 2013-11-15 | 2015-05-21 | Psma Development Company, Llc | Biomarkers for psma targeted therapy for prostate cancer |
| US20170192003A1 (en) | 2013-12-03 | 2017-07-06 | The Scripps Research Institute | Compositions and methods for fluid biopsy of melanoma |
| US20150185204A1 (en) | 2013-12-30 | 2015-07-02 | The Scripps Research Institute | Circulating tumor cell diagnostics for lung cancer |
| US20160011198A1 (en) | 2014-01-27 | 2016-01-14 | Epic Sciences, Inc. | Detection of prostate specific membrane antigen (psma) expression on circulating tumor cells (ctc) |
| EP3099821B1 (en) | 2014-01-27 | 2021-08-11 | Epic Sciences, Inc. | Circulating tumor cell diagnostics for detection of neuroendocrine prostate cancer (nepc) |
| EP3100047B1 (en) | 2014-01-27 | 2021-08-11 | Epic Sciences, Inc. | Circulating tumor cell diagnostics for prostate cancer biomarkers |
| WO2015116828A1 (en) | 2014-01-30 | 2015-08-06 | Epic Sciences, Inc. | Circulating tumor cell diagnostics for biomarkers predictive of resistance to androgen receptor (ar) targeted therapies |
| EA201691497A1 (ru) | 2014-01-31 | 2017-01-30 | Эпик Сайенсиз, Инк. | Способы детектирования и количественного определения имитаторов циркулирующих опухолевых клеток |
| EP3108246B1 (en) | 2014-02-21 | 2019-10-09 | Epic Sciences, Inc. | Methods for analyzing rare circulating cells |
| US20170285035A1 (en) | 2014-09-25 | 2017-10-05 | Epic Sciences, Inc. | Circulating tumor cell diagnostics for identification of resistance to androgen receptor targeted therapies |
| EP3207377B1 (en) | 2014-10-15 | 2024-11-06 | Epic Sciences, Inc. | Circulating tumor cell diagnostics for therapy targeting pd-l1 |
| EP3303363A4 (en) | 2015-05-29 | 2019-01-23 | Epic Sciences, Inc. | INTRAPATIENT GENOMHETEROGENICITY OF INDIVIDUAL CIRCULATIVE TUMOR CELLS (CTCS) RELATED TO PHENOTYPIC CTC HETEROGENICITY IN METASTASED, CASTING RESISTANT PROSTATE CANCER (MCRPC) |
| AU2016348401A1 (en) | 2015-11-03 | 2018-05-24 | Epic Sciences, Inc. | Single cell genomic profiling of circulating tumor cells (CTCs) in metastatic disease to characterize disease heterogeneity |
| EP3400311A4 (en) | 2016-01-06 | 2019-07-03 | Epic Sciences, Inc. | GENOMIC INDIVIDUAL CELL PROFILING OF CIRCULATING TUMOR CELLS (CTCS) IN METASTASIC DISEASE TO CHARACTERIZE THE DISEASE HETEROGENICITY |
-
2010
- 2010-10-20 ES ES10825626.4T patent/ES2556639T3/es active Active
- 2010-10-20 EP EP10825626.4A patent/EP2491395B1/en active Active
- 2010-10-20 CN CN201710186990.6A patent/CN107422127A/zh active Pending
- 2010-10-20 EP EP17205552.7A patent/EP3385716A3/en not_active Withdrawn
- 2010-10-20 JP JP2012535345A patent/JP6352588B2/ja active Active
- 2010-10-20 AU AU2010310688A patent/AU2010310688A1/en not_active Abandoned
- 2010-10-20 CN CN2010800578539A patent/CN102782498A/zh active Pending
- 2010-10-20 US US13/503,014 patent/US20120276555A1/en not_active Abandoned
- 2010-10-20 WO PCT/US2010/053431 patent/WO2011050103A1/en not_active Ceased
- 2010-10-20 CA CA2778328A patent/CA2778328C/en active Active
- 2010-10-20 CN CN202210699103.6A patent/CN115060882A/zh active Pending
- 2010-10-20 EP EP15185229.0A patent/EP3045918B1/en active Active
- 2010-10-20 ES ES15185229.0T patent/ES2661735T3/es active Active
-
2016
- 2016-05-26 AU AU2016203462A patent/AU2016203462B2/en active Active
- 2016-09-30 JP JP2016193236A patent/JP2017053860A/ja active Pending
-
2017
- 2017-05-22 US US15/601,696 patent/US20180100857A1/en not_active Abandoned
-
2018
- 2018-08-01 JP JP2018145154A patent/JP2018185339A/ja active Pending
- 2018-10-11 AU AU2018247290A patent/AU2018247290A1/en not_active Abandoned
-
2019
- 2019-01-18 US US16/252,472 patent/US10613089B2/en active Active
-
2020
- 2020-03-16 US US16/819,684 patent/US20210033612A1/en not_active Abandoned
-
2021
- 2021-04-13 AU AU2021202220A patent/AU2021202220A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018247290A1 (en) | 2018-11-01 |
| JP2013508729A (ja) | 2013-03-07 |
| AU2021202220A1 (en) | 2021-05-06 |
| JP2017053860A (ja) | 2017-03-16 |
| EP3045918B1 (en) | 2017-12-06 |
| JP2018185339A (ja) | 2018-11-22 |
| JP6352588B2 (ja) | 2018-07-04 |
| EP2491395B1 (en) | 2015-09-16 |
| EP2491395A4 (en) | 2013-05-22 |
| US10613089B2 (en) | 2020-04-07 |
| US20120276555A1 (en) | 2012-11-01 |
| EP3385716A2 (en) | 2018-10-10 |
| WO2011050103A1 (en) | 2011-04-28 |
| US20180100857A1 (en) | 2018-04-12 |
| US20190257834A1 (en) | 2019-08-22 |
| ES2661735T3 (es) | 2018-04-03 |
| CN115060882A (zh) | 2022-09-16 |
| AU2016203462B2 (en) | 2018-07-12 |
| AU2016203462A1 (en) | 2016-06-09 |
| EP3045918A1 (en) | 2016-07-20 |
| CN107422127A (zh) | 2017-12-01 |
| CA2778328A1 (en) | 2011-04-28 |
| CN102782498A (zh) | 2012-11-14 |
| CA2778328C (en) | 2018-12-18 |
| AU2010310688A1 (en) | 2012-05-17 |
| US20210033612A1 (en) | 2021-02-04 |
| EP3385716A3 (en) | 2019-01-09 |
| EP2491395A1 (en) | 2012-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2556639T3 (es) | Método para usar células no raras para detectar células raras | |
| US20230085158A1 (en) | Method of using non-rare cells to detect rare cells | |
| CA2674187C (en) | A high sensitivity multiparameter method for rare event analysis in a biological sample | |
| More et al. | Applications of imaging flow cytometry in the diagnostic assessment of red cell membrane disorders | |
| ES2765981T3 (es) | Uso del índice mitótico de células tumorales circulantes en la estratificación y diagnóstico de cáncer | |
| US20210041445A1 (en) | Methods for monitoring treatment response and disease progression in subjects using circulating cells | |
| ES2953553T3 (es) | Métodos para predecir la supervivencia global y sin progresión en sujetos que tienen cáncer usando células circulantes similares a macrófagos asociadas al cáncer (CAML) | |
| CN117501127A (zh) | 一种样本分析装置和样本分析方法 | |
| Roch-Lefèvre et al. | Suitability of the γ-H2AX assay for human radiation biodosimetry | |
| Hevessy et al. | Laboratory evaluation of a flow cytometric BCR-ABL immunobead assay | |
| US20140275292A1 (en) | Systems and methods employing human stem cell markers for detection, diagnosis and treatment of circulating tumor cells | |
| Öztürk et al. | Comparison of prostate specific antigen and neuropeptide Y parameters in patients with prostate cancer | |
| Franco et al. | Low-Grade Mammary Gland Tumors in Dogs Have Greater VEGF-A and BMP2 Immunostaining and Higher CD31 Blood Vessel Density | |
| Suzuki et al. | Artificial Intelligence Enables the Label-Free Identification of Chronic Myeloid Leukemia Cells with Mitochondrial Morphological Alterations | |
| WO2022226038A1 (en) | Compositions and methods for treatment of invasive cancers | |
| Cartwright | Cell markers | |
| Mittag et al. | Laser scanning cytometry as a tool for biomarker validation | |
| HK1140820B (en) | A high sensivity multiparameter method for rare event analysis in a biological sample |